BioPharmSignal logoBioPharmSignal

Biotech News

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

Indivior (INDV)IndiviorCompany update

Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities.

Related news

INDVIndivior2026-03-31 13:00 EST

New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

INDVIndivior2026-04-24 15:00 EST

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

View all latest news

Indivior

Addiction Medicine Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication. SUBLOCADE Franchise SUBLOCADE is a monthly extended-release buprenorphine...

Recent company news

INDVIndivior2026-08-03 10:31 EST

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

INDVIndivior2026-07-23 14:00 EST

Indivior to Report Second Quarter 2026 Financial Results and Host Webcast

INDVIndivior2026-05-20 13:00 EST

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

INDVIndivior2026-05-14 11:00 EST

Indivior to Participate in Upcoming Investor Conferences

INDVIndivior2026-05-04 11:00 EST

Indivior Announces $175 Million Accelerated Share Repurchase

Stock data

Close
36.87 USD
Market cap
3.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States